Clinical Trial Update: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) [Phase 1]

View source ↗

Summary

Phase 1 study of M9140, an anti-CEACAM5 antibody-drug conjugate, for advanced colorectal cancer is currently recruiting under the PROCEADE-CRC-01 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• M9140

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Colorectal Cancer | Phase 1 | Status: RECRUITING